{
  "id": "127c45ef-0cb4-495f-aa3a-5bca558bbdb1",
  "title": "Cathie Wood's ARK ETF adjusts portfolio with key stock trades",
  "link": "https://www.investing.com/news/company-news/cathie-woods-ark-etf-adjusts-portfolio-with-key-stock-trades-93CH-3707132",
  "description": "",
  "author": "Investing.com",
  "published": "2024-11-07 01:01:40",
  "source": "https://www.investing.com/rss/news.rss",
  "categories": null,
  "byline": "Investing.com",
  "length": 2576,
  "excerpt": "Cathie Wood's ARK ETF adjusts portfolio with key stock trades",
  "siteName": "Investing.com",
  "favicon": "",
  "text": "Cathie Wood's ARK ETFs have made a series of notable trades on Wednesday, November 6, 2024, with significant activity in the biotechnology and technology sectors. The daily trade report from ARK highlights a continued strategy of adjusting holdings in innovative companies. At the forefront of Wednesday's trades was the purchase of CRISPR Therapeutics AG (NASDAQ:CRSP) shares, with ARK acquiring a total of 409,528 shares across its ARKK and ARKG ETFs, amounting to a substantial $20,623,830 investment. This move underscores ARK's growing interest in CRSP, following additional purchases earlier in the week, suggesting a bullish outlook on the gene-editing company's prospects. ARK also increased its position in Arcturus Therapeutics (NASDAQ:) Holdings Inc (NASDAQ:ARCT), buying 67,767 shares for a total value of $1,243,524. This investment comes on the heels of previous acquisitions, indicating a sustained confidence in the company's RNA-based therapies. In another significant transaction, ARK sold 447,135 shares of SoFi Technologies Inc (NASDAQ:), with the sale valued at $5,106,281. This sale marks a notable shift in ARK's position on the personal finance company. The trading activity extended to other sectors, with ARK selling 422,560 shares of Unity Software Inc (NYSE:NYSE:) for $9,135,747, and 317,71 shares of Block Inc (NYSE:SQ) totaling $2,299,584. These divestments reflect ARK's dynamic portfolio management and its constant reevaluation of company performances and market conditions. Other purchases included 231,971 shares of AbSci Corp (NASDAQ:ABSI) and 67,874 shares of Pacific Biosciences (NASDAQ:) of California Inc (NASDAQ:PACB), indicating ARK's continued focus on cutting-edge biotech firms. Smaller trades were also part of the day's activity, with buys in companies such as Tempus AI Inc (NASDAQ:TEM), Twist Bioscience Corp (NASDAQ:), and Recursion Pharmaceuticals Inc (NASDAQ:RXRX). On the sell side, ARK reduced its stakes in Incyte Corp (NASDAQ:), Moderna Inc (NASDAQ:BMV:), and Vertex Pharmaceuticals Inc (NASDAQ:). Investors following ARK's trades can see patterns in the ETF's strategy, with a clear emphasis on innovative sectors and a willingness to adjust holdings based on both short-term and long-term market evaluations. The frequent adjustments to ARK's portfolios are a testament to Cathie Wood's active management approach, as the ETF seeks to capitalize on disruptive technologies and emerging market trends. This article was generated with the support of AI and reviewed by an editor. For more information see our T\u0026C.",
  "image": "https://i-invdn-com.investing.com/redesign/images/seo/investing_300X300.png",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv id=\"article\"\u003e\u003cp\u003eCathie Wood\u0026#39;s ARK ETFs have made a series of notable trades on Wednesday, November 6, 2024, with significant activity in the biotechnology and technology sectors. The daily trade report from ARK highlights a continued strategy of adjusting holdings in innovative companies.\u003c/p\u003e\n\u003cp\u003eAt the forefront of Wednesday\u0026#39;s trades was the purchase of CRISPR Therapeutics AG (NASDAQ:CRSP) shares, with ARK acquiring a total of 409,528 shares across its ARKK and ARKG ETFs, amounting to a substantial $20,623,830 investment. This move underscores ARK\u0026#39;s growing interest in CRSP, following additional purchases earlier in the week, suggesting a bullish outlook on the gene-editing company\u0026#39;s prospects.\u003c/p\u003e\n\u003cp\u003eARK also increased its position in Arcturus Therapeutics (NASDAQ:) Holdings Inc (NASDAQ:ARCT), buying 67,767 shares for a total value of $1,243,524. This investment comes on the heels of previous acquisitions, indicating a sustained confidence in the company\u0026#39;s RNA-based therapies.\u003c/p\u003e\n\u003cp\u003eIn another significant transaction, ARK sold 447,135 shares of SoFi Technologies Inc (NASDAQ:), with the sale valued at $5,106,281. This sale marks a notable shift in ARK\u0026#39;s position on the personal finance company.\u003c/p\u003e\n\u003cp\u003eThe trading activity extended to other sectors, with ARK selling 422,560 shares of \u003cspan itemscope=\"\" itemtype=\"http://schema.org/Corporation\"\u003e\u003cspan itemprop=\"name\"\u003e Unity Software Inc \u003c/span\u003e\u003c/span\u003e (NYSE:NYSE:) for $9,135,747, and 317,71 shares of Block Inc (NYSE:SQ) totaling $2,299,584. These divestments reflect ARK\u0026#39;s dynamic portfolio management and its constant reevaluation of company performances and market conditions.\u003c/p\u003e\n\u003cp\u003eOther purchases included 231,971 shares of AbSci Corp (NASDAQ:ABSI) and 67,874 shares of Pacific Biosciences (NASDAQ:) of California Inc (NASDAQ:PACB), indicating ARK\u0026#39;s continued focus on cutting-edge biotech firms.\u003c/p\u003e\n\u003cp\u003eSmaller trades were also part of the day\u0026#39;s activity, with buys in companies such as Tempus AI Inc (NASDAQ:TEM), Twist Bioscience Corp (NASDAQ:), and Recursion Pharmaceuticals Inc (NASDAQ:RXRX). On the sell side, ARK reduced its stakes in \u003cspan itemscope=\"\" itemtype=\"http://schema.org/Corporation\"\u003e\u003cspan itemprop=\"name\"\u003e Incyte Corp \u003c/span\u003e\u003c/span\u003e (NASDAQ:), \u003cspan itemscope=\"\" itemtype=\"http://schema.org/Corporation\"\u003e\u003cspan itemprop=\"name\"\u003e Moderna Inc \u003c/span\u003e\u003c/span\u003e (NASDAQ:BMV:), and Vertex Pharmaceuticals Inc (NASDAQ:).\u003c/p\u003e\n\u003cp\u003eInvestors following ARK\u0026#39;s trades can see patterns in the ETF\u0026#39;s strategy, with a clear emphasis on innovative sectors and a willingness to adjust holdings based on both short-term and long-term market evaluations. The frequent adjustments to ARK\u0026#39;s portfolios are a testament to Cathie Wood\u0026#39;s active management approach, as the ETF seeks to capitalize on disruptive technologies and emerging market trends.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eThis article was generated with the support of AI and reviewed by an editor. For more information see our T\u0026amp;C.\u003c/em\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "3 min read",
  "publishedTime": "2024-11-07T01:01:40Z",
  "modifiedTime": null
}
